TP63 and ovarian carcinoma: In ovarian cancer tissue, FZD7 can activate the carcinogen P63, enhance the expression of GPX4, prevent tumor cell ferroptosis, and decrease the susceptibility of drug-resistant ovarian cancer cells to ferroptosis (60).